Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$2.53M$2.53M+74.0% vs Q1 2022 Net Income-$28.16M-$28.16MN/M vs Q1 2022 EPS Diluted-$0.42-$0.42N/M vs Q1 2022 Operating Income-$29,918,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Free Cash Flowderived-$26,906,000N/M Margins · derivedOperating margin-1183.5%+117.8 pt vs Q1 2022
Net margin-1113.9%+179.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 8, 2023 · 38 d after period end